首页> 外文期刊>Gynecologie, obstetrique & fertilit >Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled 'Initial management of patients with epithelial ovarian cancer' developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa
【24h】

Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled 'Initial management of patients with epithelial ovarian cancer' developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa

机译:肿瘤标志物,评分(临床和生物)算法的诊断和预后价值,在涉嫌上皮性卵巢癌的卵巢质量面前:从法国肿瘤学指南起草的文章,标题为“上皮性卵巢癌患者的初始管理” Francogyn,CNGOF,SFOG,CNGOF的AEGIS下的Gineco-Accagy,并通过INCA认可

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives. - To evaluate the diagnostic value of serum/urinary biomarkers and the operability diagnosis strategy to make management recommendations. Methods. - Bibliographical search in French and English languages by consultation of Pubmed, Cochrane and Embase databases. Results. - For the diagnosis of a suspicious adnexal mass on imaging: Serum CA125 antigen is recommended (grade A). Serum CAE is not recommended (grade C). The low evidence in literature concerning diagnostic value of CA19.9 does not allow any recommendation concerning its use. Serum Human epididymis protein 4 (HE4) is recommended (grade A). Comparison of data concerning diagnosis value of CA125 and HE4 show similar results for the prediction of malignancy in case of a suspicious adnexal mass on imaging (NP1). Urinary HE4 is not recommended (grade A). The use of circulating tumor DNA is not recommended (grade A). Tumor associated antigen-antibodies (AAbs) is not recommended (grade B). The use of ROMA score (Risk of Ovarian Malignancy Algorithm) is recommended (grade A). The use of Copenhagen index (CPH-I), R-OPS score, OVA500 is not recommended (grade C). For the prediction of resectability of an ovarian cancer with peritoneal carcinomatosis in the context of a primary debulking surgery: It is not recommendend to use serum CA125 (grade A). The low evidence in literature concerning diagnostic value of HE4 does not allow any recommendation concerning its use in this context. No recommendation can be given concerning CA19.9 and CAE. For the prediction of resectability of an ovarian cancer with peritoneal carcinomatosis in the context of surgery after neoadjuvant chemotherapy: the low evidence in literature concerning diagnostic value of serum markers in this context does not allow any recommendation concerning their use in this context. Place of laparoscopy for the prediction of resectability in case of upfront surgery of an ovarian cancer with peritoneal carcinomatosis robust data shows that the use of laparoscopy significantly reduce futile laparotomies (LEI). Laparoscopy is recommended in this context (grade A). Fagotti score is a reproducible tool (LEI) permitting the evaluation of feasibility of an optimal upfront debulking (NP4), its use is recommended (grade C). A Fagotti score >= 8 is correlated to a low probability of complete or optimal debulking surgery (LE4) (grade C). There is no sufficient evidence to recommend the use of the modified Fagotti score or any other laparoscopic score (LE4). In case of laparotomy for an ovarian cancer with peritoneal carcinomatosis, the use of Peritoneal Cancer Index (PCI) is recommended (grade C). For the prediction of overall survival, disease free survival and the prediction of postoperative complications, the clinical and statistical of actually available tools do not allow any recommendation.
机译:目标。 - 评估血清/泌尿生物标志物的诊断价值和可操作性诊断策略进行管理建议。方法。 - 通过咨询PubMed,Cochrane和Embase数据库,以法语和英语语言搜索。结果。 - 用于诊断成像上可疑的侧型质量:建议血清CA125抗原(A级)。不推荐血清CAE(等级C)。关于CA19.9诊断价值的文献中的低证据不允许任何关于其使用的建议。建议使用血清人物附睾蛋白4(HE4)(A级)。关于CA125和HE4诊断值的数据的比较显示了在可疑侧内质量上的成像(NP1)的情况下对恶性肿瘤预测的类似结果。不推荐泌尿HE4(A级)。不推荐使用循环肿瘤DNA(A级)。不推荐肿瘤相关的抗原 - 抗体(AABS)(b级)。建议使用ROMA得分(卵巢恶性算法的风险)(A级)。不推荐使用哥本哈根指数(CPH-I),R-OPS评分,OVA500(等级C)。为了在初级剥离手术的背景下预测卵巢癌与腹膜癌的可折伤性:使用血清CA125(A级)不推荐。关于HE4诊断价值的文献中的低证据不允许在这种情况下使用的任何建议。没有建议可以关于CA19.9和CAE。在新辅助化疗后手术中与腹膜癌的腹膜癌的重新入学性预测卵巢癌的可折伤性:在这种背景下,血清标志物诊断价值的文献的低证据并不允许任何关于他们在这方面使用的建议。腹腔镜检查的位置,用于预测可重视性,以便在腹膜癌患者的卵巢癌前期手术的情况下,腹腔镜检查的使用明显减少了徒劳的剖腹术(LEI)。在此上下文中建议使用腹腔镜检查(A级)。 Fagotti评分是一种可重复的工具(LEI),允许评估最佳前期Debulking(NP4)的可行性,建议使用它(C级)。 Fagotti得分> = 8与完整或最佳消泡手术(LE4)(级别C)的低概率相关。没有足够的证据建议使用修改的Fagotti得分或任何其他腹腔镜分数(LE4)。在腹膜癌卵巢癌的腹腔切开术的情况下,建议使用腹膜癌症指数(PCI)(C级)。为了预测整体存活,无病生存和术后并发症的预测,实际可用工具的临床和统计学不允许任何建议。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号